Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

New Drug Helps Patients with Myasthenia Gravis Breathe and Speak Easier

Daniel Kim Views  

Shutterstock
Shutterstock

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s treatment for myasthenia gravis.

About 100,000 people in the U.S. suffer from myasthenia gravis, an autoimmune condition that weakens the skeletal muscles of the mouth, throat, eyes, and limbs.

Although myasthenia gravis comes in various forms, Johnson & Johnson claims that Imaavy works for over 90% of patients.

In 2020, Johnson & Johnson paid $6.5 billion to acquire Momenta, which included Imaavy. A 1,200 mg vial usually is priced at $12,480.

According to the findings of a 24-week late-stage clinical trial, Imaavy considerably improved the ability of patients with myasthenia gravis to carry out everyday tasks like speaking, breathing, and chewing. This FDA approval was based on those findings.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • 3 Daily Habits That Might Be Aging Your Brain Faster Than You Think
  • The One-Spoon Habit That’s Taking Over Healthy Mornings
  • Tired of Painful Periods? Your Pantry Might Hold the Cure
  • Still Tired After 8 Hours of Sleep? This Could Be Why
  • Scientists Link Let-7 Gene to Lung Healing—and Possibly a Cure for Fibrosis
  • GLP-1 Drugs Like Ozempic Might Cut Cancer Risk Too, Study Finds

Share it on...